Overview

• The GlycoCaging system, developed by UBC researchers, delivers drugs to the lower gut using plant-derived glycoconjugates activated by gut bacteria.
• In mice with inflammatory bowel disease (IBD), GlycoCaged drugs achieved equivalent anti-inflammatory effects at doses three to ten times lower than traditional treatments, minimizing systemic exposure.
• Human fecal studies confirmed the presence of activating gut bacteria in all samples, including those from individuals with active or remissive IBD.
• The technology has been patented, and the research team is now securing funding for advanced animal studies and human clinical trials.
• IBD affects over 322,600 Canadians, with current treatments relying on high-dose steroids that often cause severe side effects like osteoporosis, hypertension, and diabetes.